|View printer-friendly version|
Spring Bank Announces Research Agreement with The National Institute of Allergy and Infectious Diseases to Evaluate HBV Antisense Oligonucleotide Compounds
There remains a significant unmet need for easily administered antiviral and immunomodulatory therapies with favorable safety profiles that can be used in combination as a functional cure for chronic HBV.
“We are grateful to NIAID for their support of our HBV oligonucleotide antisense program,” said
For more information about Spring Bank’s HBV platform, visit springbankpharm.com/hbv-platform.
In addition, the forward-looking statements included in this press release represent Spring Bank’s views as of the date hereof.
Source: Spring Bank Pharmaceuticals, Inc.